Remarkably, blockade of TIGIT can refresh the antitumor immunity of exhausted cytotoxic T lymphocytes (CTLs) and inhibit tumor growth in a preclinical CRC tumor model [50]. This evidence concerns the gene TIGIT and colorectal carcinoma.